<DOC>
	<DOCNO>NCT02926898</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , tolerability efficacy single dose ZX008 ( Fenfluramine Hydrochloride ) add standard care add Adjunctive Antiepleptic therapy Stiripentol treatment child young adult Dravet Syndrome</brief_summary>
	<brief_title>A Two-Part Study Investigate Dose-Ranging Safety Pharmacokinetics , Followed Efficacy Safety ZX008 ( Fenfluramine Hydrochloride ) Oral Solution Adjunctive Therapy Children â‰¥2 Years Old Young Adults With Dravet Syndrome</brief_title>
	<detailed_description>This multicenter , two-cohort trial ass pharmacokinetic safety profile single dose ZX008 ( fenfluramine hydrochloride ) oral solution add Dravet syndrome treatment regimen contain VPA CLB , without STP ( Cohort 1 ) , follow randomize , double-blind , placebo-controlled parallel group evaluation efficacy , safety , tolerability ZX008 adjunctive therapy seizures child young adult Dravet syndrome ( Cohort 2 ) . Cohort 2 dose PK safety data Cohort 1 collect evaluate . The PK safety data Cohort 1 determine dose ZX008 use Cohort 2 .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Fenfluramine</mesh_term>
	<criteria>Key Subject must male nonpregnant , nonlactating female , age 2 18 year ( inclusive ) Subject must document medical history support clinical diagnosis Dravet syndrome , convulsive seizure completely control current antiepileptic drug . Subject must receive therapeutically relevant stable dose CLB , VP , STP least 4 week prior screen expect remain stable throughout study ( Cohort 2 ) . Subject must receive stable dose CLB VPA , administer twice daily , eligible Dose Regimen 1 2 subject must receive stable dose CLB , VPA , STP , administer twice daily , eligible Dose Regimen 3 ( Cohort 1 ) . Key Subject know hypersensitivity fenfluramine excipients study medication . Subject pulmonary arterial hypertension . Subject current past history cardiovascular cerebrovascular disease , cardiac valvulopathy , myocardial infarction stroke . Subject current recent history anorexia nervosa , bulimia , depression within prior year require medical treatment psychological treatment duration great 1 month . Subject current past history glaucoma . Subject receive concomitant therapy : centrallyacting anorectic agent ; monoamineoxidase inhibitor ; centrallyacting compound clinically appreciable amount serotonin agonist antagonist property , include serotonin reuptake inhibition ; triptans , atomoxetine , centrallyacting noradrenergic agonist ; cyproheptadine , and/or CYP 2D6/3A4/2B6 inhibitors/substrates . Subject currently take carbamazepine , oxcarbamazepine , eslicarbazepine , phenobarbital , phenytoin , take within past 30 day , maintenance therapy . Subject positive result urine THC Panel whole blood CBD Screening Visit . Subject clinically significant condition , clinically relevant symptom clinically significant illness 4 week prior Screening Visit , epilepsy , would negatively impact study participation , collection study data , pose risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>seizure</keyword>
	<keyword>tonic clonic</keyword>
	<keyword>epilepsy</keyword>
	<keyword>myoclonic</keyword>
	<keyword>encephalopathy</keyword>
</DOC>